α-Mangostin是一种在Garcinia mangostana果皮中提取的天然氧杂蒽酮类化合物，具有广泛的生物活性。
Cas No.:6147-11-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
α-Mangostin is a natural xanthone compound extracted from the peel of Garcinia mangostana and exhibits a wide range of biological activities[1-2]. α-Mangostin exerts anti-inflammatory effects by downregulating the NF-κB pathway, while also displaying antioxidant activity through scavenging free radicals and inhibiting ROS generation. α-Mangostin can be used in research related to cancer, antibacterial, and antiviral studies[3-4].
In vitro, treatment of MCF-7 human breast cancer cells with α-Mangostin (10–30μM) for 12–48 hours, α-Mangostin significantly upregulates MOAP-1 protein expression and promotes its interaction with activated BAX, inducing BAX oligomerization, mitochondrial cytochrome C release, and caspase activation, while downregulating BCL-XL protein levels, ultimately leading to apoptosis[5]. In HUAEC vascular endothelial cells treated with α-Mangostin (10μM) for 24 hours, α-Mangostin inhibits KDR tyrosine kinase and its phosphorylation at the Y1175 site, and suppresses cell proliferation, migration, and tube formation[6].
In vivo, in an angiotensin II-induced hypertensive C57BL/6 mouse model treated with α-Mangostin (4-8mg/kg; administered twice daily via oral gavage for 2 weeks), α-Mangostin significantly reduced systolic blood pressure, improved endothelium-dependent vasodilation, reversed aortic wall thickening and collagen deposition, downregulated aortic ACE/AT1R expression, and upregulated the ACE2/Ang-(1-7)/MasR axis activity [7]. In A375 and B16F10 cell-transplanted nude and C57BL/6 mouse melanoma models treated with α-Mangostin (10mg/kg; intraperitoneal injection every 2 days starting from day 7 after implantation), α-Mangostin significantly inhibited tumor growth and enhanced the chemotherapeutic efficacy of Cisplatin (3mg/kg)[8].
References:
[1] Majdalawieh AF, Khatib BK, Terro TM. α-Mangostin Is a Xanthone Derivative from Mangosteen with Potent Immunomodulatory and Anti-Inflammatory Properties. Biomolecules. 2025 May 7;15(5):681.
[2] Chavan T, Muth A. The diverse bioactivity of α-mangostin and its therapeutic implications. Future Med Chem. 2021 Oct;13(19):1679-1694.
[3] Liu X, Song M, Liu Y, et al. Rational Design of Natural Xanthones Against Gram-negative Bacteria. Adv Sci (Weinh). 2025 Apr;12(14):e2411923.
[4] Majdalawieh AF, Terro TM, Ahari SH, et al. α-Mangostin: A Xanthone Derivative in Mangosteen with Potent Anti-Cancer Properties. Biomolecules. 2024 Oct 30;14(11):1382.
[5] Simon SE, Lim HS, Jayakumar FA, et al. Alpha-Mangostin Activates MOAP-1 Tumor Suppressor and Mitochondrial Signaling in MCF-7 Human Breast Cancer Cells. Evid Based Complement Alternat Med. 2022 Jan 17;2022:7548191.
[6] Shiozaki T, Fukai M, Hermawati E, et al. Anti-angiogenic effect of α-mangostin. J Nat Med. 2013 Jan;67(1):202-6.
[7] Xue QQ, Liu CH, Zhang DY, et al. α-Mangostin Attenuates Blood Pressure and Reverses Vascular Remodeling by Balancing ACE/AT1R and ACE2/Ang-(1-7)/MasR Axes in Ang II-Infused Hypertensive Mice. Phytother Res. 2024 Dec;38(12):5918-5929.
[8] Xie Y, Gong C, Xia Y, et al. α-Mangostin Suppresses Melanoma Growth, Migration, and Invasion and Potentiates the Anti-tumor Effect of Chemotherapy. Int J Med Sci. 2023 Aug 6;20(9):1220-1234.
α-Mangostin是一种在Garcinia mangostana果皮中提取的天然氧杂蒽酮类化合物，具有广泛的生物活性[1-2]。α-Mangostin通过下调NF-κB通路发挥抗炎作用，同时通过清除自由基和抑制ROS生成以发挥抗氧化活性，α-Mangostin可用于癌症和抗菌抗病毒的相关研究[3-4]。
在体外，α-Mangostin（10–30μM）处理MCF-7人乳腺癌细胞12-48小时，α-Mangostin可显著上调MOAP-1蛋白表达并促进其与活化BAX的相互作用，诱导BAX寡聚化、线粒体细胞色素C释放及caspase激活，同时下调BCL-XL蛋白水平，最终导致细胞凋亡[5]。α-Mangostin（10μM）处理HUAEC血管内皮细胞24小时，α-Mangostin能抑制KDR酪氨酸激酶及其Y1175位点的磷酸化，并抑制细胞增殖、迁移及管腔形成[6]。
在体内，α-Mangostin（4-8mg/kg；每日两次灌胃给药，持续2周）处理Ang II诱导的高血压C57BL/6小鼠模型。α-Mangostin显著降低收缩压，改善内皮依赖性血管舒张功能，逆转主动脉壁增厚和胶原沉积，并下调主动脉中ACE/AT1R表达、上调ACE2/Ang-(1-7)/MasR轴活性[7]。α-Mangostin（10mg/kg；每2天腹腔注射一次，从接种后第7天开始）处理A375和B16F10细胞移植的裸鼠和C57BL/6小鼠黑色素瘤模型，α-Mangostin显著抑制肿瘤生长，并增强顺铂（3mg/kg）的化疗效果 [8]。
| Cell experiment [1]: | |
|
Cell lines |
MCF-7 and MCF-7-CR human breast cancer cells, and HaCaT human keratinocyte cells |
|
Preparation Method |
Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with α-Mangostin at various concentrations (10-30μM) for 12-48 hours. |
|
Reaction Conditions |
10-30μM; 12-48 hours. |
|
Applications |
α-Mangostin significantly induced dose-dependent apoptotic cell death in MCF-7 cells. α-Mangostin treatment led to the upregulation of endogenous MOAP-1 protein expression and downregulation of BCL-XL, while promoting the interaction between MOAP-1 and activated BAX (act-BAX). |
| Animal experiment [2]: | |
|
Animal models |
Nude mice (A375 xenograft) and C57BL/6 mice (B16F10 allograft) |
|
Preparation Method |
Mice were subcutaneously inoculated with A375 or B16F10 melanoma cells. Seven days post-implantation, mice were intraperitoneally administered α-Mangostin (10mg/kg) every two days. Mice were sacrificed, and tumors were dissected for analysis. |
|
Dosage form |
10mg/kg; i.p.; Administered every two days. |
|
Applications |
α-Mangostin significantly inhibited melanoma tumor growth in both nude mouse and C57BL/6 mouse models. α-Mangostin potentiated the anti-tumor effect of cisplatin, leading to a significantly greater reduction in tumor volume compared to monotherapy in immunocompetent C57BL/6 mice. |
|
References: |
|
| Cas No. | 6147-11-1 | SDF | |
| 别名 | α-倒捻子素; α-Mangostin | ||
| Canonical SMILES | O=C1C2=C(OC3=C1C(C/C=C(C)\C)=C(OC)C(O)=C3)C=C(O)C(C/C=C(C)\C)=C2O | ||
| 分子式 | C24H26O6 | 分子量 | 410.46 |
| 溶解度 | DMSO: ≥ 37 mg/mL (90.14 mM) | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4363 mL | 12.1815 mL | 24.3629 mL |
| 5 mM | 487.3 μL | 2.4363 mL | 4.8726 mL |
| 10 mM | 243.6 μL | 1.2181 mL | 2.4363 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet